Company Analysis
Sign in

Traws Pharma, Inc. (TRAW)

Nasdaq: TRAW · Pharmaceutical Preparations · Newtown, PA · filing with the SEC since 2003
Full chart Alerts Compare
Grade4.3
◀ Past 2.8● Present 2.4▶ Future 7.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$2.8M+1134.5%
Net income$9.2M+105.5%
Earnings per share$0.82+102.3%
Operating cash flow-$18.2M+39.0%
Cash$3.8M-82.1%
Debtn/a
Shareholders’ equity-$629,000+98.0%
Shares, diluted8,376,380+439.5%
Return on equityn/a
The recordfrom its filings
Filings in 202676
Newest filingNov 12 · EFFECT
Annual reportApr 15, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted22
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$21.6MCash from operations -$16.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 26, 2026 · SEC EDGAR · Form S-1
Listing registration
Open the filing on sec.gov
Oct 23, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TRAW · research, not advice